Erleada (apalutamide) from Janssen is used for the treatment of prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). Erleada blocks androgens such as testosterone, a hormone that can promote tumor growth. The approval of Erleada is the first to use the endpoint of “metastasis-free survival”, measuring the length of time after starting treatment that tumors did not spread in the body or that death occurred.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Oct 1st, 2018), Cerner Multum™ (updated Oct 2nd, 2018), Wolters Kluwer™ (updated Oct 2nd, 2018) and others. To view content sources and attributions, please refer to our editorial policy.